Solos Endoscopy Sales Increase by 16% for First Quarter 2012

News provided by

Apr 30, 2012, 10:08 ET

BOSTON, April 30, 2012 /PRNewswire/ -- Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased to announce that the Company expects to show a sales increase of more than 16% as compared to the same period last year when it posts its first quarter financials for period ended March 31, 2012.

Solos Endoscopy's sales increased from $84,185 for the period ended March 31, 2011 to $97,760 for the same period this year. Solos management expects the positive trend to continue as the demand for endoscopic instruments has been increasing Worldwide.

Solos Endoscopy has developed several new modifications to its endoscopic instrument lines to accommodate the continual advances in Laparoscopic surgical procedures. The significant advances over the past several years have led to a number of advantages to the patient with laparoscopic surgery versus an open procedure (laparotomy). The demand for endoscope services is increasing due to an increase in the aging and chronically ill population worldwide. Advancements in endoscopic technologies and inclusion of various types of lighting sources, video cameras, real-time conversion of data into three-dimensional images are also driving this market.

Solos Endoscopy expects to post its first quarter financials on the OTC Markets website within the next two weeks. The Company will also be releasing it's "President's Report" for distribution to its shareholders in the next thirty days.

"I am very pleased with the positive turnaround. Solos has been able to reduce its debts and increase its sales in a very short period of time. We believe the Company is well positioned for profitability," stated Bob Segersten, President of Solos Endoscopy, Inc.

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications that may arise could prevent the prompt implementation of any strategically significant plan(s) outlined above. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Annual Report filing and other filings with the Pink OTC Markets (available at www.otcmarkets.com). The company undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events, or otherwise.

CONTACT: AMANDA SEGERSTEN

[email protected]

SOURCE Solos Endoscopy, Inc.